The American Joint Commission on Cancer (AJCC) identifies five rare variants of prostate adenocarcinoma: mucinous, ductal, signet ring cell, adenosquamous and neuroendocrine including small cell. No prior study has comprehensively detailed incidence and outcomes for all AJCC variants of prostate cancer. METHODS: We used the Surveillance, Epidemiology and End Results (SEER) program to analyze prostate cancers diagnosed from 1973 to 2008. Cases of mucinous, ductal, signet ring cell, adenosquamous and neuroendocrine carcinoma were identified, along with cases of non-variant adenocarcinoma for comparison. Age-adjusted incidence rates (IRs) and overall survival (OS) were evaluated and stratified by race, age, stage and PSA. All IRs represent the number of cases per million people per year. RESULTS: Each variant is rare, with IRs between 0.03 (adenosquamous) and 0.61 (mucinous). There was a significant difference in incidence between Caucasian and African American patients with mucinous adenocarcinoma. Median OS varied ranged from 10.0 months in neuroendocrine carcinoma to 125.0 months in mucinous adenocarcinoma. In all, 5-year OS ranged from 12.6% in neuroendocrine carcinoma to 75.1% in mucinous adenocarcinoma. There was a significant difference in survival between Caucasian and African American patients for mucinous adenocarcinoma (median survival 144.0 vs 99.0 months, Po0.01). African American patients with mucinous adenocarcinoma also presented with more advanced stage disease compared with Caucasian patients. Multivariate analysis demonstrated that African American race was not associated with worse survival when corrected for stage. CONCLUSIONS: There are differences in IRs and OS among rare variants of prostate cancer. For mucinous adenocarcinoma, there are significant differences in incidence and survival between Caucasian and African American patients. These differences should be considered in clinical decision making for patients with these malignancies.
INTRODUCTION
Prostate cancer is the most common malignancy among men in the United States and the second most common cause of cancer related deaths. Approximately 240 890 cases of prostate cancer will be diagnosed and B33 720 men died from prostate cancer in the United States in 2011. The incidence of prostate cancer varies by race, with significantly higher incidence and mortality from prostate cancer among African American men compared with Caucasians. 1 The overwhelming majority of prostate cancers are adenocarcinomas, and the statistics regarding incidence and outcomes for prostate cancer are largely based on this single histology. Additionally, however, the American Joint Committee on Cancer (AJCC) defines five rare histological variants of prostate adenocarcinoma, including mucinous, ductal, signet ring cell, adenosquamous and neuroendocrine including small cell carcinoma. 2 There is very little current literature describing these variants, and to the authors' knowledge no prior study has comprehensively detailed incidence and outcomes for all AJCC variants of prostate cancer. The lack of published literature on these tumors presents obvious challenges in the clinical management of patients with rare subtypes of prostate cancer. In this study, we aim to describe the incidence and outcomes for patients with rare variants of prostate cancer using the National Cancer Institute's Surveillance, Epidemiology and End Results (SEER) database.
MATERIALS AND METHODS
We acquired our data from the SEER 17 Registry, which was released in April 2010 and includes cancers diagnosed between 1973 and 2008. This registry encompasses 17 geographical regions in the United States and includes B26.2% of the US population. The SEER population is similar to the general US population in most regards. 3 We accessed the SEER 17 registry using SEER*Stat Version 7.0.5. We identified cancers using International Classification of Diseases in Oncology (ICD-0-3) diagnosis codes for each histological variant. 4 All patients with primary prostate malignancies (topography code C61.9) classified as mucinous adenocarcinoma (ICD-0-3 codes 8480/3-8482/3), ductal adenocarcinoma (ICD-0-3 codes 8500/3-8503/3), signet ring cell carcinoma (ICD-0-3 code 8490/3), neuroendocrine or small cell carcinoma (ICD-0-3 codes 8041/3 --8045/3, 8246/3) or adenosquamous carcinoma (ICD-0-3 code 8560/3) were included in our analysis. Cases of non-variant prostate adenocarcinoma (ICD-0-3 code 8140/3) were included for comparison. We excluded cases that were designated as 'autopsy or death certificate only.' Data regarding stage at presentation were limited to patients diagnosed after 1995, as complete staging information was not available for patients diagnosed from 1973 to 1994. We used the SEER summary staging system, which classifies cases into the following stage categories: limited (corresponding to AJCC 7 th Edition stage T1-T2N0M0), regional direct (corresponding to T3N0M0), regional nodal (corresponding to TxN1-N2M0) and distant (corresponding to TxNxM1). Data regarding PSA values were available only for patients diagnosed from 2004 to 2008.
All statistics were obtained using SEER*Stat version 7.0.5 and SPSS Version 19 (IBM, Armonk, NY, USA). Our primary endpoints included ageadjusted incidence rates (IRs) and overall survival (OS) and we evaluated both of these endpoints by race. For this analysis, incidence is defined as the number of new cancers diagnosed per year and all IRs represent the number of cases per million people per year. Pearson's chi-squared tests were used to compare patient characteristics between groups. We constructed Kaplan --Meier curves and performed log-rank tests to compare survival between Caucasian and African American patients across variants of prostate cancer. OS estimates are presented along with their corresponding 95% confidence intervals. Cox univariate and multivariate proportional hazards analysis was performed when applicable to determine the impact of age, race, stage and PSA on OS. The results were considered statistically significant based on a two-sided alpha error of o0.05.
RESULTS

Patient characteristics
We identified 806 cases of mucinous adenocarcinoma, 662 cases of ductal adenocarcinoma, 130 cases of signet ring cell carcinoma, 502 cases of neuroendocrine carcinoma, 27 cases of adenosquamous carcinoma and 790 937 cases of non-variant adenocarcinoma. There were significant differences in the distribution of cancers by race, age, PSA and stage between all variants. Details regarding patient characteristics by variant are illustrated in Table 1 .
Incidence There were significant differences in incidence by variant, as shown in Table 2 . The most common of the rare variants was mucinous adenocarcinoma, with an IR of 0.61 cases per million per year, and the least common variant was adenosquamous carcinoma, with an IR of 0.03 cases per million per year. For Stage at presentation varied according to race for certain variants. For mucinous adenocarcinoma, the proportion of Caucasian patients presenting with localized, regional direct, regional nodal and distant disease was 76.1%, 19.9%, 2.0% and 2.0%, respectively, compared with 71.8%, 10.3%, 7.7% and 10.3% for African American patients (P ¼ 0.004). A similar pattern was observed in ductal adenocarcinoma, with 16.3% of African American patients presenting with distant disease compared with 7.1% of Caucasian patients; however, this difference did not reach statistical significance (P ¼ 0.067). Differences in stage at presentation by race for other variants also failed to reach statistical significance.
Overall survival
The 5-year OS varied between variants. Of the rare variants, survival was highest in mucinous adenocarcinoma, with a 5-year OS of 75.1%, and lowest in neuroendocrine carcinoma, with a 5-year OS of 12.6%. The 5-year OS for non-variant prostate adenocarcinoma was 76.5%. There were also significant differences in OS by race. In mucinous adenocarcinoma, the 5-year OS for African American men was 64.8% (95% confidence interval 54.9 --73.1%) compared with 77.2% (95% confidence interval 73.2 --80.6%) for Caucasian men. Median survival for Caucasian patients with mucinous adenocarcinoma of the prostate was 144.0 months compared with 99.0 months for African American patients (Po0.01). As illustrated in Table 3 , univariate analysis identified race (P ¼ 0.01), age (Po0.01), PSA (Po0.01) and stage (Po0.01) as factors significantly associated with OS in mucinous adenocarcinoma. However, when each of these factors was entered into a Cox multivariate model, only age (P ¼ 0.05) and stage (Po0.01) remained statistically significant. Survival details for each histological variant are shown in Table 4 , and Kaplan --Meier survival curves for each variant by race are shown in Figures 1 --4 (adenosquamous carcinoma is excluded because there were only two African American patients in our analysis with this variant).
DISCUSSION
The results of our SEER analysis highlight the significant differences in incidence and outcomes for rare histological variants of prostate adenocarcinoma as defined by the AJCC. As described above, these variants include mucinous adenocarcinoma, ductal adenocarcinoma, signet ring cell carcinoma, There were only eight patients with regional nodal disease in this cohort.
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adenosquamous carcinoma and neuroendocrine including small cell carcinoma. All of these variants are histologically distinct and have been described in case reports and retrospective series to various degrees; however, no comprehensive analysis of their epidemiological and clinical characteristics has yet been published. Our analysis represents the most comprehensive report of rare prostate cancer variants to date. Mucinous adenocarcinomas typically arise from prostate parenchyma and stain positive for prostate-specific acid phosphatase (PSAP) and PSA. 5 There are few studies on clinical outcomes in mucinous adenocarcinoma of the prostate. A retrospective analysis by Osunkoya et al. 6 of 47 patients with mucinous adenocarcinoma of the prostate who were treated with radical prostatectomy reported a 5-year biochemical relapse free survival rate of 85.4%. For comparison, a study by Han et al. reported 5-year biochemical relapse free survival of 84% in 2404 men with prostate adenocarcinoma treated with radical prostatectomy. In our analysis, 5-year OS for mucinous adenocarcinoma was similar to that of non-variant adenocarcinoma. In combination with the findings of Osunkoya et al., our results suggest that mucinous adenocarcinoma and non-variant adenocarcinoma of the prostate exhibit similar clinical behavior. Additionally, our data demonstrate that African American race is associated with higher incidence and worse survival relative to the overall cohort of patients with mucinous adenocarcinoma of the prostate. As demonstrated by the Cox multivariate model, the difference in survival between racial groups appears to be because of the fact that African American patients tend to present with more advanced stage disease. The reasons for this disparity are unclear; however, it is likely that biological, socioeconomic and sociocultural factors have a role. Ductal adenocarcinoma arises from the major prostatic ducts and histologically resembles endometrial carcinoma. It is most often found in the region of the verumontanum. Ductal adenocarcinomas of the prostate typically stain positive for PSAP and PSA. 8 The majority of these cancers present with high grade features and a primary Gleason pattern of 4, although patterns of 3 and 5 may also be seen. 9 A retrospective study of 108 patients by Tu et al. 10 including patients undergoing radical prostatectomy for ductal adenocarcinoma of the prostate demonstrated that patients with pure ductal adenocarcinoma had shorter time to local recurrence (2.8 vs 4.9 years) but longer median OS (13.8 vs 8.9 years) than patients with mixed ductal adenocarcinomas after surgery. In our study, patients with ductal adenocarcinoma of the prostate had a median OS of 84.0 months. Our results demonstrate that ductal adenocarcinoma follows a more aggressive clinical course than adenocarcinoma, and this finding appears to conflict with the results of the study by Tu et al. Further research involving higher numbers of patients is needed before conclusions regarding survival in ductal adenocarcinoma of the prostate can be definitively reached.
Signet ring cell carcinoma of the prostate is comprised of cells that are similar to signet ring cell tumors of the gastrointestinal tract. Primary signet ring cell carcinomas of the prostate typically stain positive for PSAP and PSA but negative for carcinoembryonic antigen. Warner et al.
11 published a review of nine cases of signet ring cell carcinoma of the prostate seen at the Mayo Clinic combined with 42 patients identified through review of the literature. In this study, the authors found that 33% of patients were stage IV at diagnosis with a mean survival in all patients of 28 months. In our analysis, median survival was 64.0 months for all patients. Given that our study included significantly more patients with signet ring cell carcinoma of the prostate (n ¼ 124) and that the SEER population is fairly representative of the US population as a whole, it is likely that our results more accurately reflect the outcomes of patients with signet ring cell carcinoma of the prostate.
Neuroendocrine cancers (including small cell carcinomas) of the prostate are very rare and have been infrequently described in the literature. Small cell carcinoma of the prostate is a neuroendocrine tumor that is histologically similar to small cell carcinoma of the lung and demonstrates variable staining for PSAP and PSA. These tumors generally exhibit aggressive behavior similar to their counterparts in the lung and may present with various paraneoplastic syndromes or endocrinopathies. 12 In a review of 83 patients with small cell carcinoma of the prostate by Spiess et al. 13 , 75.6% of patients presented with metastatic disease at diagnosis, and the median survival of all patients was 13.1 months. A literature review by Abbas et al. 12 found a median survival of 9.8 months and a 5-year OS of 0.9%. In our study, of patients with neuroendocrine cancers of the prostate, 51.6% of patients presented with metastatic disease, median survival was 10.0 months, and 5-year OS was 12.6%. Notably, 51.8% of patients in our study with neuroendocrine carcinoma presented with a PSA value of p5.0, which suggests that PSA screening may not be useful for detection of this disease. Our analysis confirms that small cell carcinoma of the prostate is a deadly and aggressive disease, and further research is necessary to improve detection and treatment of this often-fatal malignancy.
Adenosquamous carcinomas are characterized by the presence of both acinar and squamous components. The pathological description of these tumors in the prostate is mostly confined to case reports, with the largest published series including 33 cases. In this series, PSA and PSAP were positive in most cases.
14 About half of reported cases of adenosquamous carcinoma of the prostate have arisen in patients who have previously been treated with radiotherapy or hormonal therapy; however, the mechanism responsible for development of these tumors is poorly understood. 15 In our study, patients with adenosquamous carcinoma had a median survival of only 12.0 months and 5-year OS of 22.4%. Because of very low patient numbers, we were unable to generate any meaningful data regarding stage at presentation or PSA in these tumors. Further data on adenosquamous carcinoma of the prostate is needed in order to develop an understanding of the etiology and natural history of this disease.
One of the most striking results of our study is the significant difference in survival among patients with different histological variants of prostate cancer. The 5-year OS for adenocarcinoma of the prostate in our study was 76.5%. Outcomes for mucinous adenocarcinoma (5-year OS of 75.1%, median OS of 125.0 months) appear to be similar to those of non-variant adenocarcinoma, whereas each of the other variants are associated with significantly worse survival. Among the rare prostate cancer variants, the lowest rates of 5-year OS were observed in neuroendocrine carcinoma (12.6%) and adenosquamous carcinoma (22.4%). The differences in survival among the AJCC rare variants of prostate cancer underscore the need for further research to develop a clear understanding of the natural history and clinical presentation of these tumors.
The strengths of our study included a relatively large sample size for the cancers being studied, the use of a population-based sample, and the availability of information regarding race, age, PSA, stage and survival. The study was limited by the fact that we did not evaluate treatment patterns or survival as a function of treatment. Although the SEER data includes information regarding the use of surgery and radiation therapy, the details of these therapies (i.e., surgical reports, radiation dose and volume) are not recorded in the database. Additionally, treatments such as chemotherapy and hormone therapy, which may have an important role in the management of many of these cancers, are not documented in the SEER database. Moreover, we were unable to evaluate additional supporting data on our patients, including but not limited to family history, social history and comorbidity status. Finally, despite the use of a population-based database, the sample sizes for some of the variants studied (particularly signet ring cell and adenosquamous) were fairly small and likely did not provide enough statistical power to draw statistically significant conclusions regarding outcomes as they relate to race, age, stage at presentation and PSA.
In summary, our analysis demonstrates that the rare variants of prostate adenocarcinoma as defined by the AJCC represent a heterogeneous group of malignancies that vary significantly in terms of both incidence and OS. Additionally, we have shown that incidence, PSA, stage at presentation and survival for some of these cancers vary by race. These differences should be considered in clinical decision-making for workup and treatment of patients diagnosed with these malignancies. Future research is needed to explore the biological, socioeconomic and sociocultural factors that may account for the differences in outcomes among these variants of prostate cancer. Additionally, future research is needed to explore patterns of treatment for these malignancies with the ultimate goal of establishing a clear set of guidelines for their management.
